跳至主要内容
临床试验/CTRI/2022/01/039469
CTRI/2022/01/039469尚未招募4 期

A randomized controlled trial to assess the effect of riboflavin supplementation with antidepressant treatment in persons with major depressive disorder.

This has been submitted to DST for funding0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Subject of age 18-55 years of either gender.
  • Patients of MDD diagnosed clinically who have not started /within 15 days of antidepressant treatment
  • Patients who are prescribed any of the antidepressants (SSRI/SNRI) as monotherapy by the psychiatrist
  • Patients who can read and understand.
  • Patients who are willing to participate and give consent.

排除标准

  • Pregnant or seeking pregnancy, lactating women
  • Patients suffering from any chronic disease like cardiac diseases, respiratory diseases, liver disease, malignancy, peptic ulcer etc, which are known to affect inflammatory or neurodegenerative markers.
  • Associated neurological diseases other than depression
  • Progressive brain diseases like alzheimers disease, parkinsons disease, multiple sclerosis.

研究者

发起方
This has been submitted to DST for funding

相似试验